Personal profile
Education/Academic qualification
Critical Care, Clinical Fellowship, Mount Sinai Medical Center
Jul 1 2006 → Jun 30 2008
Award Date: Jun 30 2008
Internal Medicine, Residency, Saint Vincent's M. C. of Richmond
Jul 1 2003 → Jun 30 2006
Award Date: Jun 30 2006
MD, Bangalore Medical College
Sep 1 1994 → Nov 1 2000
Award Date: Nov 1 2000
Divisions
- Pulmonary, Critical Care and Sleep Medicine
Fingerprint
Dive into the research topics where Deepa Bangalore Gotur is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Clinical impact of idiopathic pulmonary fibrosis on SARS-CoV-2 patient outcomes: a comprehensive analysis in the pre-vaccination era
Tamimi, O., Safdar, Z., Siddiqui, N., Nisar, T. & Gotur, D., May 21 2025, In: Frontiers in Medicine. 12, 1567232.Research output: Contribution to journal › Article › peer-review
Open Access -
Respiratory physiological changes in pregnancy
Ejikeme, C., Nandakumar, V. & Gotur, D., Sep 2025, In: Respiratory Medicine. 246, p. 108245 108245.Research output: Contribution to journal › Review article › peer-review
6 Link opens in a new tab Scopus citations -
Clinical impact of pulmonary arterial hypertension on SARS-CoV-2 outcomes: U.S. pre-vaccination analysis
Tamimi, O., Ejikeme, C., Nisar, T., Gotur, D. & Safdar, Z., Aug 2024, In: Current Problems in Cardiology. 49, 8, p. 102672 102672.Research output: Contribution to journal › Review article › peer-review
Open Access -
In adults with post–COVID-19 conditions, a synbiotic preparation, SIM01, alleviated some symptoms at 6 mo
Gotur, D. & Mylonakis, E., Apr 1 2024, In: Annals of Internal Medicine. 177, 4, p. JC45Research output: Contribution to journal › Article › peer-review
Open Access1 Link opens in a new tab Scopus citations -
Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial
ACTIV-2/A5401 Study Team, Sep 2024, In: EClinicalMedicine. 75, 102787.Research output: Contribution to journal › Article › peer-review
Open Access2 Link opens in a new tab Scopus citations